[Pubmed] Impaired B cell Expression of the Inhibitory Fcγ Receptor IIB in Myasthenia Gravis

[RSS-Bot]

Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26507. Online ahead of print.

ABSTRACT

Myasthenia gravis (MG) is an autoimmune disease in which pathogenic immunoglobulin G (IgG) antibodies (Abs) bind to acetylcholine receptors (AChR) or to functionally related molecules at the neuromuscular junction. B cell expression of the inhibitory IgG receptor, FcγRIIB, maintains peripheral immune tolerance and its absence renders B cells hyperresponsive to autoantigen. Here, we report that FcγRIIB expression levels are substantially reduced in B lineage cells derived from immunotherapy-naïve patients with AChR-Ab+ early-onset MG (EOMG). In contrast, genetic variants associated with impaired FcγRIIB expression are not enriched in MG, indicating post-transcriptional dysregulation. FcγR-targeted therapies could have therapeutic benefits in MG. This article is protected by copyright. All rights reserved.

PMID:36094152 | DOI:10.1002/ana.26507


Source: https://pubmed.ncbi.nlm.nih.gov/3609415 ... 6&v=2.17.8